Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone

Drug Metabolism and Disposition

Volumn 25, Issue 10, 1997, Pages 1119-1122

  Jang, Graham R ^a,b   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; GESTODENE; LILOPRISTONE; MIFEPRISTONE; ONAPRISTONE; POLYCLONAL ANTIBODY; QUINIDINE; SULFAPHENAZOLE; TROLEANDOMYCIN;

ARTICLE; CANCER HORMONE THERAPY; CONTRACEPTION; DEMETHYLATION; DRUG METABOLISM; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PRIORITY JOURNAL;

ADULT; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; ESTRENES; FEMALE; GONANES; HORMONE ANTAGONISTS; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NORPREGNENES; OXIDOREDUCTASES, N-DEMETHYLATING; PROGESTINS; TROLEANDOMYCIN;

ORYCTOLAGUS CUNICULUS;

EID: 0030846064     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. G. H. Bakker, H. B. Setyono, H. Portengen, J. F. De. J. A. Foekens, and J. G. Klijn: Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J. Steroid Biochem. Mol. Biol. 37, 789-794 (1990).
2. M. R. Schneider, H. Michna, Y. Nishino, and M. F. el Etreby: Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J. Steroid Biochem. Mol. Biol. 37, 783- 787 (1990).
3. M. F. Lin, M. H. Kawachi, M. R. Stallcup, S. M. Grunberg. and F. F. Lin: Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 26, 194-204 (1995).
4. S. M. Grunberg, M. H. Weiss, I. M. Spit, J. Ahmadi, A. Sadun, C. A. Russell, L. Lucci, and L. L. Stevenson: Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J. Neurosurg. 74, 86- 866 (1991).
5. L. M. Kettel, A. A. Murphy, A. J. Morales, and S. S. Yen: Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Human Reprod. 1, 116-120 (1994).
6. M. C. Batista, T. P. Cartledge, A. W. Zellmer, M. J. Merino, C. Axiotis, D. L. Loriaux, and L. K. Nieman: Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy. Am. J. Obstet. Gynecol. 167, 60- 65 (1992).
7. K. L. Greene, L. M. Kettel, and S. S. Yen: Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential. Fertil. Steril. 58, 338-343 (1992).
8. C. P. Puri and P. F. A. Van Look: Newly developed competitive progesterone antagonists for fertility control. In "Antihormones in Health and Disease. Frontiers of Hormone Research" (M. K. Agarwal, ed.), pp. 127-167. Karger, New York, 19491.
9. P. F. A. Van Look and H. Von Hetzen: Antiprogestins: perspectives from a global research program. In "Clinical Applications of Mifepristone (RU 486) and Other Antiprogestins" (M. S. Donaldson, L. Dorflinger, S. S. Brown, and L. Z. Benet, eds.), pp. 253-277. National Academy Press. Washington, D.C., 1993.
10. O. Heikinheimo and R. Kekkonen: Dose-response relationships of RU 486. Ann. Med. 25, 71-76 (1993).
11. G. R. Jang, S. A. Wrighton, and L. Z. Benet: Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem. Pharmacol. 52, 753-761 (1996).
12. P. K. Smith, R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano. E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk: Measurement of protein using bicinchoninic acid [published erratum appears in Anal. Biochem. 163, 279 (1987)]. Anal. Biochem. 150, 76-85 (1985).
13. T. Omura and R. Sato: The carbon monooxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378 (1964)
14. O. Heikinheimo, O. Ylikorkala, U. Turpeinen. and P. Lahteenmaki: Pharmacokinetics of the antiprogestcrone RU 486: no correlation to clinical performance of RU 486. Acta Endocrinol. (Copenh.) 123, 298-304 (1990).
15. C. Zurth and F. Kagels: Determination of onapristone and its N-desmethyl metabolite in human plasma or serum by high-performance liquid chromatography. J. Chromatogr. 532, 115-123 (1990).
16. D. J. Newton, R. W. Wang, and A. Y. Lu: Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
17. S. Chasserot-Golaz, P. Parcollet, and G. Beck: Interrelationship between RU38486 and the P450 activities in rat liver. J. Steroid Biochem. 34, 473-478 (1989).